An international study led by Dr. Fred Saad has resulted in the approval of a new treatment for metastatic castration-resistant prostate cancer. On December 16, the European Commission gave its positive endorsement to this combination treatment, a first for this stage of the disease. 

More specifically, it concerns the use of Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer for whom chemotherapy is not clinically indicated. 

To read AstraZeneca’s press release on this topic, click here.